First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – A real-world experience from Israel

First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – A real-world experience from Israel

ObjectiveCutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin cancer worldwide. It is usually treated surgically, with very high cure rates. However, in 3%-7% of cases, cSCC metastasizes to lymph nodes or distant organs. Many of the affected patients are elderly with...

Full description

Bibliographic Details
Main Authors: Itamar Averbuch, Saeed Salman, Noa Shtamper, Ilana Doweck, Aron Popovtzer, Gal Markel, Daniel Hendler, Inbar Finkel, Assaf Moore, Eyal Fenig, Tarek Taha, Kamel Mhameed, Noga Kurman, Salem Billan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
PD-1 inhibitor
cemiplimab
pembrolizumab
radiotherapy
cutaneous squamous cell carcinoma (cSCC)
real-world experience
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1117804/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1117804/full

Similar Items